EGFR and colorectal carcinoma: For instance, several clinical studies are evaluating ICIs and the anti-EGFR mAb cetuximab as a therapeutic combination in CRC since cetuximab can modulate the immune composition of the TME, potentially making cancer cells more susceptible to ICIs [240].